DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Capravirine to Treat Children With HIV Infection

Phase 1

Completed

Conditions: HIV Infection

First Posted Date: 2000-11-24

Last Posted Date: 2006-07-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT00006519

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

Recruiting

Conditions: Primary Effusion Lymphoma
Multicentric Castleman's Disease
Kaposi's Sarcoma
HIV
Lymphomas

First Posted Date: 2000-11-23

Last Posted Date: 2025-05-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 999

Registration Number: NCT00006518

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Late Effects of Treatment for Sarcomas in Children

Completed

Conditions: Sarcoma

First Posted Date: 2000-11-22

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00006515

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression

Phase 2

Completed

Conditions: Diabetes Mellitus Type 1

Interventions: Drug: Islet Transplantation

First Posted Date: 2000-11-20

Last Posted Date: 2021-04-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 6

Registration Number: NCT00006505

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors

Phase 2

Completed

Conditions: Brain Tumor

First Posted Date: 2000-11-08

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT00006450

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Phase 2

Active, not recruiting

Conditions: Lymphoma, AIDS-related
Lymphoma, Large B-Cell, Diffuse

Interventions: Biological: Rituximab
Biological: Filgrastim
Drug: EPOCH

First Posted Date: 2000-11-06

Last Posted Date: 2024-08-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 68

Registration Number: NCT00006436

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study of Plexiform Neurofibromas in Neurofibromatosis Type 1

Completed

Conditions: NF1
Plexiform Neurofibromas

First Posted Date: 2000-11-06

Last Posted Date: 2020-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00006435

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study

Completed

Conditions: Breast Cancer

First Posted Date: 2000-11-01

Last Posted Date: 2020-11-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00006425

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study

Completed

Conditions: Breast Cancer

First Posted Date: 2000-10-30

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 200

Registration Number: NCT00006421

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

Phase 3

Completed

Conditions: Liver Cirrhosis
Esophageal and Gastric Varices
Portal Hypertension

Interventions: Drug: Timolol Maleate
Drug: Placebo

First Posted Date: 2000-10-06

Last Posted Date: 2017-06-01

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 213

Registration Number: NCT00006398

Locations: 🇬🇧
Royal Free Hospital, Hampstead, London, United Kingdom
🇺🇸
The Faulkner Hospital, Boston, Massachusetts, United States
🇪🇸
Hospital Clinic I Provincial de Barcelona, Barcelona, Catalonia, Spain

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy